• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Bimokalner

Acousia Therapeutics’ ACOU085 signal puts Kv7.4 activation in focus for hearing loss prevention

By Pallavi Madhiraju on June 12, 2026   Pharma & Biotech  

Acousia Therapeutics’ ACOU085 signal puts Kv7.4 activation in focus for hearing loss prevention

Read how Acousia Therapeutics’ bimokalner Phase 2a signal could reshape cisplatin hearing loss prevention in adults.

Recent Posts

  • Could Phinomics’ circular DNA platform expose the blind spots slowing cancer drug development?
  • Volta Labs and Twist Bioscience push target enrichment closer to walk-away automation
  • Why Medtronic’s Scientia Vascular acquisition matters for stroke device workflows
  • Could Simcere’s Stanford Medicine IPF deal expose the next big gap in fibrosis treatment?
  • Acousia Therapeutics’ ACOU085 signal puts Kv7.4 activation in focus for hearing loss prevention
  • AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
  • Is Lateral Pharma’s pain platform quietly opening a new biotech battleground?
  • Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race
  • Baxter faces FDA early alert as Volara circuit leakage risk threatens respiratory care
  • Penumbra’s THUNDERBOLT clearance strengthens Boston Scientific’s pending vascular device bet
  • Why Blood Cancer United’s luveltamab move could change rare pediatric cancer access
  • Amgen turns to Duke as FDA scrutiny puts Tavneos rare autoimmune disease role at risk
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes